Melissa Aldinger
Overview
Explore the profile of Melissa Aldinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Zailik A, Sager J, Sanchez-Pearson Y, Parra S, Moore J, Sarkar P, et al.
Clin Pharmacol Ther
. 2024 Dec;
117(3):759-767.
PMID: 39668507
Sotrovimab is a recombinant human monoclonal antibody for the early treatment of mild-to-moderate COVID- 19. A phase I, open-label, randomized, parallel-group study was conducted to investigate the pharmacokinetics, relative bioavailability,...
2.
Subramanian S, Schnell G, di Iulio J, Gupta A, Shapiro A, Sarkis E, et al.
Future Virol
. 2023 Dec;
PMID: 38074312
Sotrovimab is an engineered human monoclonal antibody that binds a conserved region of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab for treatment of mild to moderate...
3.
Satram S, Ghafoori P, Reyes C, Keeley T, Birch H, Brintziki D, et al.
J Patient Rep Outcomes
. 2023 Sep;
7(1):92.
PMID: 37702920
Background: The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at...
4.
Moya J, Temech M, Parra S, Juarez E, Hernandez-Loy R, Gutierrez J, et al.
Open Forum Infect Dis
. 2023 Jul;
10(7):ofad344.
PMID: 37520411
Background: Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be well tolerated and efficacious against pre-Omicron strains in treating patients with mild to moderate coronavirus disease 2019...
5.
Sager J, El-Zailik A, Passarell J, Roepcke S, Li X, Aldinger M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2023 Mar;
12(6):853-864.
PMID: 36922886
Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent progression to hospitalization or death in non-hospitalized high-risk patients with mild to moderate coronavirus disease 2019 following...
6.
Maher M, Soriaga L, Gupta A, Chen Y, di Iulio J, Ledoux S, et al.
Cell Rep Med
. 2022 Aug;
3(8):100721.
PMID: 35977462
Understanding who is at risk of progression to severe coronavirus disease 2019 (COVID-19) is key to clinical decision making and effective treatment. We study correlates of disease severity in the...
7.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D, et al.
JAMA
. 2022 Mar;
327(13):1236-1246.
PMID: 35285853
Importance: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of...
8.
Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci D, et al.
N Engl J Med
. 2021 Oct;
385(21):1941-1950.
PMID: 34706189
Background: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent...